menu search

IMGN / ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance. Read More
Posted: Nov 3 2023, 13:32
Author Name: Zacks Investment Research
Views: 022891

IMGN News  

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

By Zacks Investment Research
November 3, 2023

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The compan more_horizontal

Analyzing The Acquisition Potential Of ImmunoGen

By Seeking Alpha
October 31, 2023

Analyzing The Acquisition Potential Of ImmunoGen

ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European more_horizontal

3 Examples of How Moneyness Impacts Options Trading

By Schaeffers Research
September 1, 2023

3 Examples of How Moneyness Impacts Options Trading

Subscribers to  Chart of the Week  received this commentary on Sunday, August 27. more_horizontal

ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?

By Seeking Alpha
August 29, 2023

ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?

Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuxi more_horizontal

ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical

By Market Watch
August 28, 2023

ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical

Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with more_horizontal

Options Bears Break Bank With Biotech Stock Puts

By Schaeffers Research
August 8, 2023

Options Bears Break Bank With Biotech Stock Puts

Subscribers to Schaeffer's Event Trader  service scored a 272% profit with our  ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation. more_horizontal

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
July 31, 2023

ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0 more_horizontal

ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors

By Zacks Investment Research
July 17, 2023

ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors

ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke throug more_horizontal


Search within

Pages Search Results: